9,364 Shares in Enovis Corporation $ENOV Bought by Fiduciary Financial Group LLC

Key Points

• Fiduciary Financial Group LLC has acquired 9,364 shares of Enovis Corporation, valued at approximately $309,000, during the second quarter according to their latest SEC filing.
• Enovis reported earnings of $0.79 per share, beating analyst expectations, with a revenue of $564.5 million for the last quarter, marking a 7.5% increase year-over-year.
• CEO Damien McDonald increased his holdings by acquiring 6,457 shares, while several research firms have adjusted their price targets, with a consensus target now set at $51.00.

Fiduciary Financial Group LLC acquired a new position in shares of Enovis Corporation (NYSE:ENOV - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,364 shares of the company's stock, valued at approximately $309,000.

Other large investors have also added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in Enovis by 0.7% in the 4th quarter. California State Teachers Retirement System now owns 52,236 shares of the company's stock valued at $2,292,000 after buying an additional 350 shares during the last quarter. Humankind Investments LLC increased its stake in shares of Enovis by 8.6% during the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company's stock worth $217,000 after purchasing an additional 452 shares during the last quarter. US Bancorp DE increased its stake in shares of Enovis by 2.5% during the 1st quarter. US Bancorp DE now owns 19,031 shares of the company's stock worth $727,000 after purchasing an additional 462 shares during the last quarter. Leisure Capital Management increased its stake in shares of Enovis by 2.2% during the 1st quarter. Leisure Capital Management now owns 22,903 shares of the company's stock worth $875,000 after purchasing an additional 489 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its stake in shares of Enovis by 266.7% during the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after purchasing an additional 536 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis Trading Down 1.8%

ENOV stock traded down $0.60 during midday trading on Friday, reaching $32.58. 211,366 shares of the company traded hands, compared to its average volume of 1,172,403. Enovis Corporation has a 52-week low of $25.47 and a 52-week high of $49.83. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25. The business has a 50 day moving average of $29.68 and a 200-day moving average of $32.60. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of -2.29 and a beta of 1.68.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.05. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The business had revenue of $564.50 million for the quarter, compared to the consensus estimate of $555.80 million. During the same period in the prior year, the business posted $0.62 earnings per share. The company's quarterly revenue was up 7.5% compared to the same quarter last year. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. As a group, sell-side analysts expect that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ENOV. Wells Fargo & Company reduced their price objective on shares of Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a research note on Friday, August 8th. Needham & Company LLC reduced their price objective on shares of Enovis from $57.00 to $49.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. UBS Group reduced their price objective on shares of Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Evercore ISI reduced their price objective on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Finally, Canaccord Genuity Group reduced their price objective on shares of Enovis from $70.00 to $58.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $51.00.

Insider Activity

In other Enovis news, CEO Damien Mcdonald bought 6,457 shares of the business's stock in a transaction dated Thursday, September 11th. The shares were purchased at an average price of $30.97 per share, with a total value of $199,973.29. Following the completion of the purchase, the chief executive officer owned 102,753 shares in the company, valued at $3,182,260.41. This represents a 6.71% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was purchased at an average cost of $29.71 per share, for a total transaction of $74,275.00. Following the purchase, the chief financial officer owned 116,729 shares of the company's stock, valued at $3,468,018.59. This represents a 2.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 12,157 shares of company stock valued at $374,760. 2.70% of the stock is currently owned by insiders.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.